CNH Partners LLC purchased a new position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 153,377 shares of the company’s stock, valued at approximately $7,055,000. CNH Partners LLC owned about 0.17% of Neurocrine Biosciences as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently modified their holdings of the company. ARS Investment Partners LLC purchased a new position in shares of Neurocrine Biosciences in the 2nd quarter worth about $207,000. Stephens Inc. AR purchased a new position in shares of Neurocrine Biosciences in the 2nd quarter worth about $207,000. Cubist Systematic Strategies LLC boosted its holdings in shares of Neurocrine Biosciences by 151.5% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 5,301 shares of the company’s stock worth $244,000 after buying an additional 3,193 shares during the last quarter. Tudor Investment Corp ET AL purchased a new position in shares of Neurocrine Biosciences in the 2nd quarter worth about $250,000. Finally, Grandfield & Dodd LLC boosted its holdings in shares of Neurocrine Biosciences by 15.2% in the 2nd quarter. Grandfield & Dodd LLC now owns 6,130 shares of the company’s stock worth $282,000 after buying an additional 810 shares during the last quarter.

A number of equities analysts recently weighed in on NBIX shares. Robert W. Baird reissued an “outperform” rating and issued a $66.00 price target on shares of Neurocrine Biosciences in a report on Thursday, September 21st. Jefferies Group LLC reissued a “buy” rating and issued a $69.00 price target (up from $66.00) on shares of Neurocrine Biosciences in a report on Tuesday, October 3rd. BidaskClub raised shares of Neurocrine Biosciences from a “sell” rating to a “hold” rating in a report on Wednesday, June 21st. Oppenheimer Holdings, Inc. reissued an “outperform” rating and issued a $70.00 price target on shares of Neurocrine Biosciences in a report on Wednesday, July 5th. Finally, Cowen and Company reaffirmed an “outperform” rating and set a $65.00 price objective (up from $60.00) on shares of Neurocrine Biosciences in a report on Wednesday, August 9th. Two research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $68.44.

In other news, insider Haig P. Bozigian sold 22,500 shares of Neurocrine Biosciences stock in a transaction dated Friday, August 4th. The stock was sold at an average price of $50.00, for a total transaction of $1,125,000.00. Following the transaction, the insider now directly owns 154,601 shares of the company’s stock, valued at approximately $7,730,050. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Christopher Flint Obrien sold 52,817 shares of Neurocrine Biosciences stock in a transaction dated Tuesday, September 5th. The shares were sold at an average price of $57.50, for a total value of $3,036,977.50. Following the transaction, the insider now directly owns 101,790 shares in the company, valued at $5,852,925. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 132,580 shares of company stock worth $7,440,850. Insiders own 4.80% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “CNH Partners LLC Invests $7.06 Million in Neurocrine Biosciences, Inc. (NBIX)” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this news story on another site, it was illegally copied and republished in violation of US & international copyright and trademark laws. The original version of this news story can be viewed at https://www.thecerbatgem.com/2017/10/08/cnh-partners-llc-invests-7-06-million-in-neurocrine-biosciences-inc-nbix.html.

Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) traded down 0.18% during midday trading on Friday, hitting $62.44. 583,747 shares of the stock were exchanged. Neurocrine Biosciences, Inc. has a 52-week low of $37.35 and a 52-week high of $63.77. The firm’s 50 day moving average price is $57.19 and its 200-day moving average price is $50.50. The stock’s market cap is $5.51 billion.

Neurocrine Biosciences (NASDAQ:NBIX) last released its quarterly earnings results on Thursday, August 3rd. The company reported ($0.68) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.67) by ($0.01). The business had revenue of $6.34 million during the quarter, compared to analyst estimates of $0.61 million. During the same period in the prior year, the company posted ($0.46) EPS. On average, equities research analysts expect that Neurocrine Biosciences, Inc. will post ($2.45) earnings per share for the current fiscal year.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.

Want to see what other hedge funds are holding NBIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neurocrine Biosciences, Inc. (NASDAQ:NBIX).

Institutional Ownership by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Stock Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related stocks with our FREE daily email newsletter.